PRED-G
LOE ApproachingNDAOPHTHALMICSUSPENSION/DROPS
Approved
Jun 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRED-G is an ophthalmic suspension approved in 1988 for eye-related indications as a small-molecule therapeutic. The drug is administered as drops directly to the eye and represents a mature product in AbbVie's ophthalmology portfolio. Mechanism of action and specific indications are not publicly detailed in available records.
LOE Approaching
Product is in mature LOE-approaching phase with moderate competitive pressure (30/100), signaling potential team consolidation and reduced headcount expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PRED-G offers limited new career growth opportunities with zero linked job openings and a product in LOE-approaching phase. Roles on this product typically involve defensive market management, cost optimization, and preparation for post-LOE generic competition rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on PRED-G at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.